Metastatic Breast Cancer, Version 1.2012

Carlson, R. W.; Allred, D. Craig; Anderson, Benjamin O.; Burstein, Harold J.; Edge, Stephen B.; Farrar, William B.; Forero, Andres; Giordano, Sharon H.; Goldstein, Lori J.; Gradishar, William J.; Hayes, Daniel F.; Hudis, Clifford A.; Isakoff, Steven J.; Ljung, Britt Marie; Mankoff, David A.; Marcom, P. Kelly; Mayer, Ingrid A.; McCormick, Beryl; Pierce, Lori J.; Reed, Elizabeth; Smith, Mary Lou; Soliman, Hatem; Somlo, George; Theriault, Richard L.; Ward, John H.; Wolff, Antonio C.; Zellars, Richard C.; Kumar, Rashmi; Shead, Dorothy A.

doi:10.6004/jnccn.2012.0086

Cited by 95 publications

(36 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Improving and targeting treatment of metastatic breast cancer (MBC) has been shown to improve survival by approximately 30 % [2]. Given the efficacy and low morbidity of endocrine therapy for estrogen-receptor-expressing (ER+) tumors and the lack of efficacy of endocrine therapy in ER-negative (ER-) tumors, assay for ER expression in histologic tumor samples is critical to select treatment for MBC [3–5]. While ER expression is readily determined in biopsy material from primary breast tumors, biopsy of metastatic sites is more technically challenging and may be associated with higher morbidity.…”

Section: Introductionmentioning

confidence: 99%

A Phase 2 Study of 16α-[18F]-fluoro-17β-estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC)

et al. 2013

Self Cite

View full text Add to dashboard Cite

Purpose 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) quantifies estrogen receptor (ER) expression in tumors and may provide diagnostic benefit. Procedures Women with newly diagnosed metastatic breast cancer (MBC) from an ER-positive primary tumor were imaged before starting endocrine therapy. FES uptake was evaluated qualitatively and quantitatively, and associated with response and with ER expression. Results Nineteen patients underwent FES imaging. Fifteen had a biopsy of a metastasis and 15 were evaluable for response. Five patients had quantitatively low FES uptake, six had at least one site of qualitatively FES-negative disease. All patients with an ER-negative biopsy had both low uptake and at least one site of FES-negative disease. Of response-evaluable patients, 2/2 with low FES standard uptake value tumors had progressive disease within 6 months, as did 2/3 with qualitatively FES-negative tumors. Conclusions Low/absent FES uptake correlates with lack of ER expression. FES-positron emission tomography can help identify patients with endocrine resistant disease and safely measures ER in MBC.

show abstract

Section: Introductionmentioning

confidence: 99%

A Phase 2 Study of 16α-[18F]-fluoro-17β-estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC)

et al. 2013

Self Cite

View full text Add to dashboard Cite

show abstract

“…There is now an urgent need for phase III randomized clinical trials addressing this particular question. European (ESMO) and American (NCCN) recommendations propose different options in different settings according to the available data [51,52]. Anti-HER2 therapy should be the treatment of choice in all patients with HER2-positive MBC.…”

Section: Resultsmentioning

confidence: 99%

Targeted Therapies in HER2-Overexpressing Metastatic Breast Cancer

et al. 2016

View full text Add to dashboard Cite

Human epidermal growth factor receptor-2 (HER2) is amplified in 25-30% of breast cancers and is associated with aggressive disease and poorer survival. Multiple anti-HER2 targeted therapies have dramatically changed management and outcome of this subgroup, both in adjuvant and metastatic settings. Despite the improvement of survival thanks to trastuzumab, unclear mechanisms of resistance occur, which has led to the development of new anti-HER2 therapies such as lapatinib, pertuzumab, and trastuzumab emtansine (T-DM1). The optimal sequence of the available drugs is still not well established. All this progress raises the question of toxicity that need to be managed, especially with longer survival of patients. In this article, we review different anti-HER2 therapies used in HER2-positive m etastatic breast cancer.

show abstract

“…SLN techniques are now part of the standard treatment for breast cancer, 16 melanoma, 17 and selected cases of vulvar cancer. 18 The application of the SLN concept for malignancies of intra-abdominal organs is still under evaluation and testing.…”

Section: Discussionmentioning

confidence: 99%

Minilaparoscopy and Sentinel Lymph Node in Uterine Cancer

Ferreira

Nogueira‐Silva

Miranda

et al. 2015

CRSLS

View full text Add to dashboard Cite

Background: The sentinel lymph node (SLN) concept might minimize surgical aggressiveness in gynecological oncology, namely in cervical and endometrial malignancies. Therefore, we assessed the feasibility of SLN identification, dissection, and harvesting by using minilaparoscopic surgical instruments in an animal model. We compared the minilaparoscopic approach, which is known to bring important advantages, with the use of conventional laparoscopic instruments.

show abstract

Metastatic Breast Cancer, Version 1.2012

Cited by 95 publications

References 16 publications

A Phase 2 Study of 16α-[18F]-fluoro-17β-estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC)

A Phase 2 Study of 16α-[18F]-fluoro-17β-estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC)

Targeted Therapies in HER2-Overexpressing Metastatic Breast Cancer

Minilaparoscopy and Sentinel Lymph Node in Uterine Cancer

Contact Info

Product

Resources

About